PA & NP Medical Guidance | Clinical Diagnosis & Treatment

Latest Features

more features >>

NP/PA Practice Corner

CME/CE

Hypertrophic Cardiomyopathy (HCM): Breakthrough Treatments Targeting Novel Mechanisms
Activity Type: Hosted

HCM: Breakthrough Treatments Targeting Novel Mechanisms

AMA PRA Category 1 Credit(s)TM, CE for Pharmacists
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder that involves unexplained left ventricular (LV) hypertrophy, often caused by pathogenic variants in sarcomere genes.
Unmet Needs in Current Treatment Approaches for Hypertrophic Cardiomyopathy
Activity Type: Hosted

Unmet Needs in Current Treatment Approaches for HCM

AMA PRA Category 1 Credit(s)TM, CE for Pharmacists
This CMEO Snack highlights the recommendations from the 2020 AHA/ACC Guidelines for the Diagnosis and Treatment of Patients with HCM, including the importance of multidisciplinary care and new agents that have the potential to improve care and outcomes of patients with HCM.

More